Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

NCT04218552 ↗

Phase 2 Completed 176 enrolled Addpharma Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the optimal dose of AD-209 in patients with Essential Hypertension.

Timeline

Start: 2020-02-25
Primary completion: 2021-02-25
Completion: 2021-02-25

Outcome

Met primary endpoint

paper The MSSBP and mean sitting diastolic BP in the quarter-dose and half-dose groups were significantly lower compared to the placebo and amlodipine 5 mg groups. PMID 36094783 ↗

Publications

Sung KC, Sung JH, Cho EJ, Ahn JC, Han SH, Kim W, Kim KH, Sohn IS, Shin J, Kim SY, Kim KI, Kang SM, Park SJ, Kim YJ, Shin JH, Park SM, Park CG. Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. J Clin Hypertens (Greenwich). 2022 Oct;24(10):1298-1309. doi: 10.1111/jch.14570. Epub 2022 Sep 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AD209	Unknown	—	Oral
Comparator	Amlodipine	Other / unclassified	5 mg	Oral
Comparator	Amlodipine	Other / unclassified	10 mg	Oral
Comparator	Telmisartan	Other / unclassified	80 mg	Oral